Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Assets (2020 - 2025)

Apellis Pharmaceuticals has reported Non-Current Assets over the past 6 years, most recently at $60.4 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $60.4 million for Q4 2025, down 37.13% from a year ago — trailing twelve months through Dec 2025 was $273.8 million (up 19.53% YoY), and the annual figure for FY2025 was $60.4 million, down 37.13%.
  • Non-Current Assets for Q4 2025 was $60.4 million at Apellis Pharmaceuticals, down from $68.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for APLS hit a ceiling of $96.1 million in Q4 2024 and a floor of $20.5 million in Q1 2024.
  • Median Non-Current Assets over the past 5 years was $43.5 million (2022), compared with a mean of $47.5 million.
  • Biggest five-year swings in Non-Current Assets: plummeted 47.63% in 2023 and later soared 329.02% in 2024.
  • Apellis Pharmaceuticals' Non-Current Assets stood at $57.7 million in 2021, then decreased by 29.5% to $40.7 million in 2022, then plummeted by 44.96% to $22.4 million in 2023, then soared by 329.02% to $96.1 million in 2024, then tumbled by 37.13% to $60.4 million in 2025.
  • The last three reported values for Non-Current Assets were $60.4 million (Q4 2025), $68.0 million (Q3 2025), and $65.8 million (Q2 2025) per Business Quant data.